Calypso and Siemens have already demonstrated the feasibility of multileaf collimator (MLC) tracking through a partnership with the German Cancer Research Center, a biomedical research institute in Germany.
MLC tracking enables the radiation beam to move in concert with the tumor target based on real-time tracking data provided by the Calypso system, thereby enabling faster, more precise delivery of radiation with a higher degree of accuracy and confidence.
Holger Schmidt, CEO of oncology care systems for Siemens Healthcare, said: "We are very pleased with the master development agreement with Calypso Medical as this will allow us to more rapidly develop new approaches for the delivery of radiation therapy. We believe our technologies complement one another ideally and once fully integrated may lead to improved outcomes and a better quality-of-life for all cancer patients."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index